Oxford Biomedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of cell and gene therapy products in Europe and internationally. The company operates in two segments, Platform and Product. Its LentiVector platform technology integrates genes into non-dividing cells, including neurons in the brain and retinal cells in the eye, as well as accommodates various therapeutic genes. The company's products under development stage include Axo-Lenti-PD, a gene-based treatment for parkinson's disease; OXB-302, which is in pre-clinical stage for the treatment of haematological tumours; OXB-401 that is in pre-clinical stage for the treatment of liver indication; OXB-40X for liver indication; and OXB-40Y for liver indication. The company has partnerships with Novartis, Bristol Myers Squibb, Sio Gene Therapies, Orchard Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium, Immatics, Arcellx, and Vaccines Manufacturing and Innovation Centre. The company also has a research collaboration agreement with Circularis Biotechnologies to identify novel tissue specific promoters for in vivo lentiviral gene therapy products; Virica Biotech for scaling of viral medicines; Isolere Bio provides a platform technology for tackling downstream inefficiencies in the manufacturing of biologics; and BiologIC Technologies provides novel biocomputer system for viral vector development. Oxford Biomedica plc was founded in 1995 and is headquartered in Oxford, the United Kingdom.

Oxford Biomedica plc

Kriya Therapeutics develops gene therapies for conditions affecting millions of people globally, with a focus on making these therapies accessible. The company targets areas of high unmet need, utilizing innovative gene therapy approaches.

Kriya Therapeutics

OXB provides contract development and manufacturing organization (CDMO) services specializing in viral vectors for cell and gene therapies. The company offers end-to-end capabilities including development, production, and regulatory expertise. OXB collaborates with pharmaceutical and biotech companies to support their clinical and commercial needs.

Metric
Company Name	Oxford Biomedica plc	Kriya Therapeutics
Symbol	OXB
MSH ID	COM:OXB	COM:KRIYATHERAPEUTICS
Market	STOCKS	PRIVATE
Sector	Healthcare	Healthcare & Health Services
Industry	Biotechnology	Biotechnology
Country	GB	US
Stage		Series C
Employee Count	703
Website	oxb.com	kriyatherapeutics.com
LinkedIn
Founders

Metric
Market Cap	4.54M
Enterprise Value
Monthly Web Traffic		2.88K
Web Traffic Growth		-0.93
Valuation
Raised Capital		150M

Metric
Revenue	114.09M
Revenue (LTM)
Revenue (NTM)
Gross Profit	49.95M
EBITDA	-76.64M
Operating Income	-113.89M
Net Income	-200.68M
EPS	-2.08
Diluted EPS	-2.08
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.46
Operating Profit Margin	-0.73
EBITDA Margin	-0.67
Net Profit Margin	-0.52
Return on Equity	-0.33
Return on Assets	-0.15
Return on Capital Employed	-0.25

COM:OXB

OXB

Last Close

420.00

25/11 09:17

Market Cap

3.56M

Beta: -

Volume Today

74.18K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-3.78
P/B Ratio	0.83
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	4.55
EV Multiple	-3.73

Metric
Days Sales Outstanding
Days Payables Outstanding	70.13
Days Inventory Outstanding	98.27
Operating Cycle	194.56
Cash Conversion Cycle	133.07
Asset Turnover	0.40

Metric
Operating Cash Flow	-36.19M
Free Cash Flow	-48.72M
Cash Flow to Debt	0.01
Operating Cash Flow/Sales	0.01
Free Cash Flow Yield	-0.16

Metric
Cash & Equivalents	132.16M
Accounts Receivable	36.69M
Inventory	16.40M
Goodwill
Debt to Capitalization	0.40
Debt to Assets	0.25
Current Ratio	3.61
Quick Ratio	2.97

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.05
R&D to Revenue	0.44
SG&A to Revenue	0.20